The IN AA-loaded SLNs also inhibited tau hyperphosphorylation, glial activation, and lipid peroxidation in AD rats induced by Aβ1-42, indicating their potential in treating the early stages of AD [150]. The gene discussed is MAPT; the disease is Alzheimer disease.